These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 37733182)
1. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Xing F; Qin Y; Xu J; Wang W; Zhang B Mol Biotechnol; 2024 Sep; 66(9):2396-2414. PubMed ID: 37733182 [TBL] [Abstract][Full Text] [Related]
2. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer. Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer. Kang K; Li X; Peng Y; Zhou Y Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387 [TBL] [Abstract][Full Text] [Related]
4. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma. Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma. Yang F; Niu X; Zhou M; Li W Sci Rep; 2024 Jun; 14(1):14436. PubMed ID: 38910181 [TBL] [Abstract][Full Text] [Related]
6. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer. Pan G; Xie H; Xia Y Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551 [TBL] [Abstract][Full Text] [Related]
7. Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma. Chen P; Yu J; Luo Q; Li J; Wang W BMC Gastroenterol; 2023 Nov; 23(1):382. PubMed ID: 37946148 [TBL] [Abstract][Full Text] [Related]
8. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer. Xiao L; Yin W; Chen X; Zhang X; Zhang C; Yu Z; Lü M Sci Rep; 2023 Nov; 13(1):20135. PubMed ID: 37978247 [TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs. Yang X; Zhang Y; Liu J; Feng Y Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515 [TBL] [Abstract][Full Text] [Related]
10. Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma. Chen D; Li Q; Xu Y; Wei Y; Li J; Zhu X; Li H; Lu Y; Liu X; Yan D Cancer Cell Int; 2023 Dec; 23(1):316. PubMed ID: 38066643 [TBL] [Abstract][Full Text] [Related]
11. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning. Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D Front Genet; 2023; 14():1193944. PubMed ID: 37456667 [No Abstract] [Full Text] [Related]
12. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma. Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243 [TBL] [Abstract][Full Text] [Related]
13. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility. Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671 [TBL] [Abstract][Full Text] [Related]
14. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma. Xue W; Qiu K; Dong B; Guo D; Fu J; Zhu C; Niu Z Cancer Cell Int; 2023 Sep; 23(1):218. PubMed ID: 37759294 [TBL] [Abstract][Full Text] [Related]
15. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer. Xiong Y; Kong X; Mei H; Wang J; Zhou S Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma. Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725 [TBL] [Abstract][Full Text] [Related]
17. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma. Guo Z; Xie Y; Zhang L; Liu S; Jiang W Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745 [TBL] [Abstract][Full Text] [Related]
18. Disulfidptosis-related lncRNA signature reveals immune microenvironment and novel molecular subtyping of stomach adenocarcinoma. Li J; Xia C; Song Y; Zhang L; Shang W; Xu N; Lu Q; Liang D Heliyon; 2024 Apr; 10(8):e29005. PubMed ID: 38628708 [TBL] [Abstract][Full Text] [Related]
19. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma. Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539 [TBL] [Abstract][Full Text] [Related]
20. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma. Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M Front Genet; 2022; 13():989719. PubMed ID: 36212154 [No Abstract] [Full Text] [Related] [Next] [New Search]